[go: up one dir, main page]

FI120349B - Förfarande för producering av en fusionspolypeptid - Google Patents

Förfarande för producering av en fusionspolypeptid Download PDF

Info

Publication number
FI120349B
FI120349B FI20075159A FI20075159A FI120349B FI 120349 B FI120349 B FI 120349B FI 20075159 A FI20075159 A FI 20075159A FI 20075159 A FI20075159 A FI 20075159A FI 120349 B FI120349 B FI 120349B
Authority
FI
Finland
Prior art keywords
antigen
particles
binding
amino acid
epitopes
Prior art date
Application number
FI20075159A
Other languages
English (en)
Finnish (fi)
Other versions
FI20075159L (sv
FI20075159A0 (sv
Inventor
Kalle Saksela
Original Assignee
Next Biomed Technologies Nbt O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Next Biomed Technologies Nbt O filed Critical Next Biomed Technologies Nbt O
Publication of FI20075159A0 publication Critical patent/FI20075159A0/sv
Priority to FI20075159A priority Critical patent/FI120349B/sv
Priority to CA002680123A priority patent/CA2680123A1/en
Priority to MX2009009503A priority patent/MX2009009503A/es
Priority to EP08718564A priority patent/EP2129689A4/en
Priority to AU2008223755A priority patent/AU2008223755A1/en
Priority to JP2009552239A priority patent/JP2010520266A/ja
Priority to US12/530,019 priority patent/US8735328B2/en
Priority to CN200880015324A priority patent/CN101679514A/zh
Priority to PCT/FI2008/050111 priority patent/WO2008107523A2/en
Publication of FI20075159L publication Critical patent/FI20075159L/sv
Application granted granted Critical
Publication of FI120349B publication Critical patent/FI120349B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/161—HIV-1, HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p.7, p6, p66/68, p51/52, p31/34, p32, p40

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (8)

1. Förfarande för producering av en fusionspolypeptid, som kan bindas specifikt samtidigt tili ätminstone tvä epitoper av en som varierande känd polypeptidantigen, de 5 nämnda epitopema bestäende av den nämnda antigenens 3-5 successiva konserverade aminosyrarester, vilket förfarande omfattar stegen: a) 3 - 5 aminosyror länga konserverade regioner väljs fran antigenen genom en datoranalys pä antigenens kända aminosyrasekvenser; 10 b) peptider som baserar sig pä de valda konserverade regionerna i antigenen produceras; c) ett bibliotek pä partiklar som uttrycker bindningsproteiner bringas i kontakt med en eller flera nämnda peptider; 15 d) de partiklar som uttrycker bindningsproteiner med bindningsaktivitet mot peptiderna isoleras; e) en nukleinsyra som har erhällits eller härletts frän den/de i steg d) isolerade 20 partikeln/partiklarna utsätts för mutagenes; f) ett bibliotek pä partiklar som uttrycker bindningsproteiner produceras pä basis av de i steg e) erhällna partiklarna; 25 g) det i steg f) erhällna biblioteket bringas i kontakt med en eller flera nämnda peptider eller ett fragment därav; h) de partiklar som uttrycker bindningsproteiner med en förbättrad bindningsaktivitet mot de nämnda peptiderna eller ett fragment därav isoleras; 30 i) stegen e) - h) upprepas en eller flera gänger; j) partiklar som kan bindas specifikt till den nämnda antigenens ätminstone 3 - 5 successiva aminosyror länga epitop tas frän de i steg i) erhällna partiklarna; 5 k) den nämnda fusionspolypeptiden produceras pä basis av de i steg j) isolerade partiklarna genom att kombinera i en fusionspolypeptid bindningsspecificiteten pä de tvä nämnda partiklarna som har specificitet för den nämnda antigenens ätminstone tvä olika epitoper, vilket leder till en fusionspolypeptid med en hög specificitet i förhällande till den nämnda antigenens varianter. 10
2. Förfarande enligt patentkrav 1, varvid den i steg k) erhällna nämnda fusionspolypeptiden bindas specifikt till 95 %, 95,5 %, 96 %, 96,5 %, 97 %, 97,5 %, 98 %, 98,5 %, 99 %, 99,5 % eller 100 % av den nämnda antigenens varianter. 15
3. Förfarande enligt patentkrav 1, varvid det nämnda biblioteket är ett fagbibliotek pä enkelkedjiga antikroppar.
4. Förfarande enligt patentkrav 1, varvid den nämnda antigenen är HIV:s p24-polypeptid. 20
5. Förfarande enligt patentkrav 4, varvid den nämnda peptiden har valts frän 3-5 aminosyror länga regioner i HIV:s p24-polypeptid, vilka regioner bestär av följande: NAWVK, FRDY, RAEQ, NPDC, VGGP, AWVK, NAWV, RDY, FRD, AEQ, RAE, PDC, NPD, GGP, VGG, WVK, AWV, NAW, SDI, PVG, GLN, WMT, TLL, EMM och HKA. 25
6. Förfarande enligt patentkrav 1, varvid epitoperna bestär av 3 - 4 eller 4-5 successiva aminosyrarester.
7. Förfarande enligt patentkrav 1, varvid den ena eller bäda av epitoperna bestär av 3, 4 30 eller 5 successiva aminosyrarester.
8. Förfarande enligt patentkrav 1, varvid den nämnda fusionspolypeptidens affinitet i förhällande tili antigenen är 10"12 - 10~15 M.
FI20075159A 2007-03-07 2007-03-07 Förfarande för producering av en fusionspolypeptid FI120349B (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FI20075159A FI120349B (sv) 2007-03-07 2007-03-07 Förfarande för producering av en fusionspolypeptid
AU2008223755A AU2008223755A1 (en) 2007-03-07 2008-03-07 A fusion polypeptide for detection of conserved combinatorial or composite epitopes in non-conserved proteins
MX2009009503A MX2009009503A (es) 2007-03-07 2008-03-07 Un polipeptido de fusion para deteccion de epitopos combinatorios conservados o compuestos en proteinas no conservadas.
EP08718564A EP2129689A4 (en) 2007-03-07 2008-03-07 FUSION POLYPEPTIDE FOR DETECTING COMBINATION OR COMPOSITE EPITOPES PRESERVED IN NON-PRESERVED PROTEINS
CA002680123A CA2680123A1 (en) 2007-03-07 2008-03-07 A fusion polypeptide for detection of conserved combinatorial or composite epitopes in non-conserved proteins
JP2009552239A JP2010520266A (ja) 2007-03-07 2008-03-07 非保存性タンパク質内の、保存性のコンビナトリアルエピトープまたは複合エピトープを検出するための融合ポリペプチド
US12/530,019 US8735328B2 (en) 2007-03-07 2008-03-07 Fusion polypeptide for detection of conserved combinatorial or composite epitopes in non-conserved proteins
CN200880015324A CN101679514A (zh) 2007-03-07 2008-03-07 用于检测非保守蛋白质中保守的组合或复合表位的融合多肽
PCT/FI2008/050111 WO2008107523A2 (en) 2007-03-07 2008-03-07 A fusion polypeptide for detection of conserved combinatorial or composite epitopes in non-conserved proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20075159 2007-03-07
FI20075159A FI120349B (sv) 2007-03-07 2007-03-07 Förfarande för producering av en fusionspolypeptid

Publications (3)

Publication Number Publication Date
FI20075159A0 FI20075159A0 (sv) 2007-03-07
FI20075159L FI20075159L (sv) 2008-09-08
FI120349B true FI120349B (sv) 2009-09-30

Family

ID=37930071

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20075159A FI120349B (sv) 2007-03-07 2007-03-07 Förfarande för producering av en fusionspolypeptid

Country Status (9)

Country Link
US (1) US8735328B2 (sv)
EP (1) EP2129689A4 (sv)
JP (1) JP2010520266A (sv)
CN (1) CN101679514A (sv)
AU (1) AU2008223755A1 (sv)
CA (1) CA2680123A1 (sv)
FI (1) FI120349B (sv)
MX (1) MX2009009503A (sv)
WO (1) WO2008107523A2 (sv)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7176724B2 (ja) 2018-07-20 2022-11-22 国立大学法人滋賀医科大学 ヒト末梢性コリン作動性神経検出用抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO314588B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
US6610472B1 (en) 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
GB0305702D0 (en) * 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies

Also Published As

Publication number Publication date
US8735328B2 (en) 2014-05-27
FI20075159L (sv) 2008-09-08
MX2009009503A (es) 2010-02-17
CN101679514A (zh) 2010-03-24
CA2680123A1 (en) 2008-09-12
FI20075159A0 (sv) 2007-03-07
EP2129689A1 (en) 2009-12-09
AU2008223755A1 (en) 2008-09-12
US20100190655A1 (en) 2010-07-29
JP2010520266A (ja) 2010-06-10
EP2129689A4 (en) 2011-11-02
WO2008107523A2 (en) 2008-09-12
WO2008107523A8 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
CN114163523B (zh) 一种针对新型冠状病毒的单域抗体及其应用
CN112010966B (zh) 一种针对新冠病毒棘突蛋白非rbd区的单克隆抗体及其应用
KR102229225B1 (ko) 사스-코로나바이러스-2 표면의 스파이크 단백질에 결합하는 사스-코로나바이러스 감염증의 진단용 결합 분자
US5086002A (en) Erythrocyte agglutination assay
US7049060B2 (en) HCV anti-core monoclonal antibodies
EP0759037B1 (en) Antigen/antibody specificity exchanger
CN111748032B (zh) 抗新型冠状病毒的抗体和使用该抗体的免疫检测
US20030129587A1 (en) Antigen/antibody specificity exchanger
CN104903727A (zh) 诊断、预后、治疗和筛选方案
FI120349B (sv) Förfarande för producering av en fusionspolypeptid
FI120376B (sv) Förfarande för producering av en biomodifierad polypeptid med hög affinitet
CN109503711A (zh) 一种用于血凝方法检测pcv2病毒的双功能纳米抗体、编码基因及其应用
US20200017582A1 (en) Immunoassay method using anti-human bnp fragment (4-32) antibody
FI112501B (sv) Hevein-bindande monoklonala antikroppar
Liu et al. Bispecific monoclonal antibodies against a viral and an enzyme: utilities in ultrasensitive virus ELISA and phage display technology
Qiu et al. A camel anti-lysozyme CDR3 only domain antibody selected from phage display VHH library acts as potent lysozyme inhibitor
EP4194054A1 (en) Camelid antibodies for use in therapy and diagnosis
CN119119270B (zh) 一种抗Human CD24单克隆抗体、其制备方法及其应用
Chen et al. Isolation of human antibodies against hepatitis E virus from phage display library by immobilized metal affinity chromatography
Twair et al. Production of polyclonal antibody against M13 phage for application in nanobody technology
TW201943727A (zh) 單域結合蛋白及其組合及多種標記單域結合蛋白之應用及用於特異性過敏原ＩｇＥ的檢測方法
US20230228763A1 (en) Process for direct readout of immunoglobulins
Kramer et al. Antibodies for biosensors
TWI532838B (zh) 蓖麻子毒素融合瘤細胞株、其單株抗體、及包含該單株抗體的免疫檢測試劑及套組
de Marco Isolation of recombinant antibodies that recognize native and accessible membrane biomarkers

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120349

Country of ref document: FI

MM Patent lapsed